

Funder	Project Title	Funding	Institution
Autism Speaks	Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes	\$0	Stanford University
Autism Speaks	Randomized controlled trial of oxytocin treatment for social deficits in children with autism	\$53,600	Stanford University
Autism Speaks	Randomized phase 2 trial of RAD001 (an mTOR inhibitor) in patients with tuberous sclerosis complex	\$0	Boston Children's Hospital
Autism Speaks	A multi-site double-blind placebo-controlled trial of memantine vs. placebo in children with autism	\$0	Holland Bloorview Kids Rehabilitation Hospital
Health Resources and Services Administration	Controlled trial of sertraline in young children with Fragile X Syndrome	\$285,943	University of California, Davis
Health Resources and Services Administration	Treatment of Overweight Induced by Antipsychotic Medication in Young People with ASD	\$468,376	Holland Bloorview Rehabilitation Hospital
National Institutes of Health	ACE Center: Augmenting language interventions for ASD: A translational approach	\$269,087	University of California, Los Angeles
National Institutes of Health	The role of vasopressin in the social deficits of autism	\$235,500	Stanford University
National Institutes of Health	Piloting treatment with insulin-like growth Factor-1 in Phelan-McDermid syndrome	\$366,363	Mount Sinai School of Medicine
National Institutes of Health	ACE Network: Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)	\$2,435,695	University of North Carolina at Chapel Hill
Simons Foundation	Testing the use of helminth worm ova in treating autism spectrum disorders	\$0	Montefiore Medical Center
Simons Foundation	Evaluation of a melanocortin agonist to improve social cognition in autism	\$74,675	University of Sydney